News & Media

Press Releases

Alizé Pharma 3 Announces Rebranding to Amolyt Pharma, Reflecting a Strategic Focus on Building and Advancing a Portfolio of Therapeutic Peptides for Rare Endocrine and Metabolic Diseases

Alizé Pharma 3 Announces Rebranding to Amolyt Pharma, Reflecting a Strategic Focus on Building and Advancing a Portfolio of Therapeutic Peptides for Rare Endocrine and …

Download a PDF: EN or FR

Alizé Pharma 3 raises €67 million ($75 million) in Series A from a strong international syndicate

Amolyt Pharma 3 announces that it has completed a €67 million Series A financing round …

Download a PDF: EN or FR

Alizé Pharma 3 moves forward with building a transatlantic biopharmaceutical company focused on rare endocrine and metabolic diseases

Announces a key addition to its leadership team and the structuring of its product portfolio in line with its ambition to become a leading global rare disease company …

Download a PDF: EN or FR

Upcoming events

Date: March 20-23, 2021

Learn more about the conference »

Social Updates

TWITTER

Scroll to Top